Tokyo, Japan
Tokyo, Japan

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar , an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development , is headquartered in Parsippany, New Jersey.Daiichi Sankyo Europe, GmbH , the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations . In 2009, the highly respected magazine R&D Direction honoured Daiichi Sankyo with its "Best Cardiovascular Pipeline Award". Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Daiichi Sankyo | Date: 2017-05-17

It is intended to provide a novel compound or a salt thereof, or crystals of the compound or the salt, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. [Solution] The present invention provides a pyridone derivative having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or a salt thereof, or crystals of the compound or the salt (wherein R_(1), R_(2), R_(3), R_(4), R_(5), W, X, Y, and Z are each as defined in the specification).


Patent
Daiichi Sankyo | Date: 2017-01-25

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), and V in the formula (I) are each as defined in the present specification).


A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.


The invention provides methods of treating or preventing bleeding events or over- anticoagulation in a subject in need thereof who is identified as having sensitivity to a vitamin K antagonist such as warfarin by administering to the subject a therapeutically effective amount of an FXa inhibitor, which can be a direct or indirect FXa inhibitor, or a warfarin or VKA alternative drug or compound. The direct FXa inhibitor can be the small molecule edoxaban p- toluenesulfonate monohydrate, edoxaban, or a pharmaceutically acceptable salt and/or hydrate thereof. In aspects, the subject is identified as having one or more genetic polymorphisms in genes CYP2C9 and/or VKORC1 resulting in loss of function, reduction in function, or aberrant function of these genes and/or their protein products, and sensitivity to warfarin. The invention provides methods of administering an FXa inhibitor or warfarin alternative to safely and effectively reduce, prevent, reduce the risk of, prevent the recurrence of, or prevent the risk of recurrence of, conditions such as embolism, thrombosis, thromboembolism, etc. in a subject who is in need of anticoagulant therapy and who is identified as having one or more genetic polymorphisms resulting in warfarin sensitivity.


Provided is a medicine for reducing and/or ameliorating growth failure induced by the administration of a steroid during a growth period, the medicine containing at least one type of natriuretic peptide receptor B (NPR-B) agonist as an active ingredient.


Patent
Daiichi Sankyo | Date: 2017-03-22

A method of producing a compound of formula (I) or a pharmacologically acceptable salt thereof, useful as a therapeutic agent and/or a preventive agent for pain or for a sodium channel associated disease:^(1) and Ar^(2): a heteroaryl group or an aryl group, each optionally substituted; R^(1), R^(2) and R^(3): a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group or a C3-C7 cycloalkyl group or a cyano group; R^(4) and R^(5): a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a hydroxyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C3-C7 cycloalkyl group or a C1-C6 alkoxy group; and n: an integer of 1 to 3, comprising a step of removing a protecting group P from the compound of formula (VI):


Patent
National Cancer Center and Daiichi Sankyo | Date: 2017-01-25

It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.


Patent
Daiichi Sankyo | Date: 2017-02-15

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L^(1)-L^(2)-L^(P)-NH-(CH_(2))n^(1)-L^(a)-L^(b)-L^(c) or -L^(1)-L^(2)-L^(P)-wherein the anti-HER2 antibody is connected to the terminal L^(1), and the antitumor compound is connected to the terminal L^(c) or L^(P) with the nitrogen atom of the amino group at position 1 as the connecting position.


An object of the present invention is to provide a high-purity crystal of a compound represented by formula (1a) that is an activated blood coagulation factor X (FXa) inhibitor. Solution: High-purity crystals of a compound represented by the following formula (1a):


Patent
Daiichi Sankyo | Date: 2017-01-09

The present invention provides methods for manufacturing neuraminic acid derivatives. [Means for solution] Methods for manufacturing compounds represented by the formula (I): [wherein R^(1 )represents a C_(1)-C_(19 )alkyl group], or a pharmacologically acceptable salt thereof, using N-acetylneuraminic acid dihydrate as a starting raw material are provided.

Loading Daiichi Sankyo collaborators
Loading Daiichi Sankyo collaborators